🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525217-31-00
Authorised Phase I

A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms

2026-525217-31-00 · tracked via the Priya Life Science EU tracker
Sponsor
Incyte Corp.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
10/08/2026
Enrollment target
60
Sites
Italy, Belgium, Germany, France, Spain

Condition studied

Myeloproliferative Neoplasms

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525217-31-00 on CTIS ↗ ← All trials in the EU